Lindsay T. Fourman

Lindsay T. Fourman

Auto-generated profile, based on publicly available information

Lindsay T. Fourman

Metabolism Unit, Massachusetts General Hospital, Boston, MA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2025 in JAMA Network Open
Verified
Journal Article
Open access
LFLindsay T. Fourman
Lindsay T. Fourman
AAAya Awwad
Aya Awwad
AGAlba Gutiérrez-Sacristán
Alba Gutiérrez-Sacristán
CDCamille A. Dash
Camille A. Dash
JJJulia E. Johnson
Julia E. Johnson
SGSteven K. Grinspoon
Steven K. Grinspoon
Importance: A recent Lancet Commission proposed an obesity definition that integrates body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]) with anthropometric measures, marking a paradigm shift in how obesity is conceptualized and classified.Objective: To determine the clinical implications of the new definition of obesity.Design, Setting, and Participants: This population-based longitudinal cohort study leveraged data from the All of Us cohort. Participants in All of Us with complete anthropometric data were enrolled between May 31, 2017, and September 30, 2023, with a median follow-up of 4.0 (IQR, 1.7-4.7) years.Exposure: Obesity classified by traditional and new definitions.Main Outcomes and Measures: Obesity was defined by the new framework using sex- and race-specific thresholds as (1) BMI above the traditional obesity threshold plus at least 1 elevated anthropometric measure or BMI greater than 40 (BMI-plus-anthropometric obesity) or (2) at least 2 elevated anthropometric measures with BMI below the traditional obesity threshold (anthropometric-only obesity). Obesity was categorized as clinical or preclinical based on organ dysfunction and/or physical limitation.Results: Among 301 026 individuals (183 633 [61.0%] female; median age, 54 [IQR, 38-65] years), 206 361 (68.6%) had obesity according to the new definition vs 128 992 (42.9%) according to the traditional definition, due to inclusion of individuals with anthropometric-only obesity. Among the overall cohort, 108 650 individuals (36.1%) had clinical obesity according to the new definition; this prevalence increased with age, as 24 498 of 45 018 individuals 70 years or older (54.4%) had clinical obesity. Compared with no obesity, odds ratios of organ dysfunction were 3.31 (95% CI, 3.24-3.37) for BMI-plus-anthropometric obesity and 1.76 (95% CI, 1.73-1.80) for anthropometric-only obesity per the new definition. In longitudinal analyses, clinical obesity conferred elevated risks of incident diabetes (adjusted hazard ratio [AHR], 6.11; 95% CI, 5.67-6.60), cardiovascular events (AHR, 5.88; 95% CI, 5.38-6.43), and all-cause mortality (AHR, 2.71; 95% CI, 2.41-3.05) compared with no obesity or organ dysfunction. Preclinical obesity was also associated with increased risks of incident diabetes (AHR, 3.32; 95% CI, 3.08-3.58) and cardiovascular events (AHR, 1.40; 95% CI, 1.27-1.55), albeit to a lesser degree.Conclusions and Relevance: In this cohort study, adoption of the new definition of obesity significantly increased obesity prevalence with major implications for clinical practice and public policy. The new framework effectively stratified individuals at high risk of organ dysfunction and long-term complications while introducing anthropometric-only obesity and preclinical obesity as distinct entities warranting further study.

9 February 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
LFLindsay T Fourman
Lindsay T Fourman
SGSteven K Grinspoon
Steven K Grinspoon
Lipodystrophy constitutes a spectrum of diseases characterized by a generalized or partial absence of adipose tissue. Underscoring the role of healthy fat in maintenance of metabolic homeostasis, fat deficiency in lipodystrophy typically leads to profound metabolic disturbances including insulin resistance, hypertriglyceridemia, and ectopic fat accumulation. While rare, recent genetic studies indicate that lipodystrophy is more prevalent than has been previously thought, suggesting considerable underdiagnosis in clinical practice. In this article, we provide an overview of the etiology and management of generalized and partial lipodystrophy disorders. We bring together the latest scientific evidence and clinical guidelines and expose key gaps in knowledge. Through improved recognition of the lipodystrophy disorders, patients (and their affected family members) can be appropriately screened for cardiometabolic, noncardiometabolic, and syndromic abnormalities and undergo treatment with targeted interventions. Notably, insights gained through the study of this rare and extreme phenotype can inform our knowledge of more common disorders of adipose tissue overload, including generalized obesity.

29 March 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
MOMollie W Ockene
Mollie W Ockene
SRSamuel C Russo
Samuel C Russo
HLHang Lee
Hang Lee
CMCarmen Monthé-Drèze
Carmen Monthé-Drèze
TSTakara L Stanley
Takara L Stanley
LFLindsay T Fourman
Lindsay T Fourman
Context Since the initial outbreak of coronavirus disease 2019 (COVID-19), a novel population of children with in utero exposure to maternal infection has emerged whose health outcomes are largely unknown. Objective To compare longitudinal growth trajectories among infants with vs without in utero COVID-19 exposure. Methods We conducted a longitudinal cohort study leveraging a prospectively enrolled perinatal biorepository among 149 infants with in utero COVID-19 exposure and 127 unexposed controls. Weight, length, and body mass index (BMI) were abstracted from health records at 0, 2, 6, and 12 months and standardized using World Health Organization growth charts. Analyses were adjusted for maternal age, ethnicity, parity, insurance, and BMI as well as infant sex, birthdate, and breastfeeding. Results Infants with in utero COVID-19 exposure vs controls exhibited differential trajectories of weight and BMI, but not length, z-score over the first year of life (study group × time interaction, P < .0001 for weight and BMI). Infants born to mothers with prenatal COVID-19 had lower BMI z-score at birth (effect size: −0.35, 95% CI −0.66 to −0.03) and greater gain in BMI z-score from birth to 12 months (effect size: 0.53, 95% CI 0.06 to 0.99). Birth weight z-score mediated a significant proportion of the relationship between COVID-19 exposure and postnatal growth (estimate ± SE, 32 ± 14%, P = .02). Conclusion Infants with in utero COVID-19 exposure exhibited lower birth weight and accelerated weight gain in the first year of life, which may be harbingers of downstream cardiometabolic pathology. Further studies are needed to delineate cardiometabolic sequelae among this emerging global population.

20 August 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
LFLindsay T. Fourman
Lindsay T. Fourman
JBJames M. Billingsley
James M. Billingsley
GAGeorge Agyapong
George Agyapong
SSShannan J. Ho Sui
Shannan J. Ho Sui
MFMeghan N. Feldpausch
Meghan N. Feldpausch
SGSteven K. Grinspoon
Steven K. Grinspoon
Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity among people living with HIV that has a more aggressive course than NAFLD among the general population. In a recent randomized placebo-controlled trial, we demonstrated that the growth hormone–releasing hormone analog tesamorelin reduced liver fat and prevented fibrosis progression in HIV-associated NAFLD over 1 year. As such, tesamorelin is the first strategy that has shown to be effective against NAFLD among the population with HIV. The current study leveraged paired liver biopsy specimens from this trial to identify hepatic gene pathways that are differentially modulated by tesamorelin versus placebo. Using gene set enrichment analysis, we found that tesamorelin increased hepatic expression of hallmark gene sets involved in oxidative phosphorylation and decreased hepatic expression of gene sets contributing to inflammation, tissue repair, and cell division. Tesamorelin also reciprocally up- and downregulated curated gene sets associated with favorable and poor hepatocellular carcinoma prognosis, respectively. Notably, among tesamorelin-treated participants, these changes in hepatic expression correlated with improved fibrosis-related gene score. Our findings inform our knowledge of the biology of pulsatile growth hormone action and provide a mechanistic basis for the observed clinical effects of tesamorelin on the liver.

3 December 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
LFLindsay T Fourman
Lindsay T Fourman
TSTakara L Stanley
Takara L Stanley
MOMollie W Ockene
Mollie W Ockene
CMColin M McClure
Colin M McClure
MTMabel Toribio
Mabel Toribio
SGSteven K Grinspoon
Steven K Grinspoon
Human immunodeficiency virus (HIV)–associated nonalcoholic fatty liver disease (NAFLD) is characterized by a high prevalence of hepatic fibrosis as a strong clinical predictor of all-cause and liver-specific mortality risk. We leveraged data from an earlier clinical trial to define the circulating proteomic signature of hepatic fibrosis in HIV-associated NAFLD. A total of 183 plasma proteins within 2 high-multiplex panels were quantified at baseline and at 12 months (Olink Cardiovascular III; Immuno-Oncology). Twenty proteins were up-regulated at baseline among participants with fibrosis stages 2–3 versus 0–1. Proteins most differentially expressed included matrix metalloproteinase 2 (P < .001), insulin-like growth factor–binding protein 7 (P = .001), and collagen α1(I) chain (P = .001). Proteins were enriched within pathways including response to tumor necrosis factor and aminopeptidase activity. Key proteins correlated directly with visceral adiposity and glucose intolerance and inversely with CD4+ T-cell count. Within the placebo-treated arm, 11 proteins differentially increased among individuals with hepatic fibrosis progression over a 12-month period (P < .05). Among individuals with HIV-associated NAFLD, hepatic fibrosis was associated with a distinct proteomic signature involving up-regulation of tissue repair and immune response pathways. These findings enhance our understanding of potential mechanisms and biomarkers of hepatic fibrosis in HIV.

21 May 2025 in Current Opinion in HIV and AIDS
Verified
Journal Article
Closed access
AGArijeet K. Gattu
Arijeet K. Gattu
LFLindsay T. Fourman
Lindsay T. Fourman
Purpose of review: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among people with HIV (PWH) and increasingly recognized as a major contributor to morbidity and mortality. The field of MASLD is rapidly evolving with adoption of a new nomenclature and approval of the first FDA-approved therapy within the past year. These developments underscore the need to consider the current state of the science specifically in the context of HIV. Recent findings: MASLD in PWH (MASLD-HIV) follows a more aggressive clinical course compared to HIV-negative individuals. While MASLD-HIV shares common pathogenic mechanisms with MASLD in the general population, HIV-specific factors – including altered body composition, chronic immune activation, enhanced gut permeability, and antiretroviral therapy – exacerbate disease progression. Despite an expanding pipeline of MASLD therapies, a critical gap remains in evaluating these interventions specifically among PWH. Nonetheless, dedicated studies of glucagon-like peptide-1 receptor agonists and the growth hormone-releasing hormone analog tesamorelin have shown promise in MASLD-HIV. Summary: MASLD is a key contributor to liver-related and cardiovascular-morbidity in PWH. While there have been exciting advances to improve diagnosis and management of MASLD in the general population, differences in MASLD pathophysiology demonstrate the need to tailor our approach specifically for PWH.